article Open AccessTop 1% cited
Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study
Nephrology Dialysis Transplantation · 2009 · Vol. 25(4) · pp. 1251–1257
Hitoshi Kumagai✉(National Defense Medical College)Toshiya EbataKenji Takamori(Juntendo University Urayasu Hospital)Taro Muramatsu(Keio University)Hidetomo NakamotoHiromichi Suzuki(Saitama Medical University Hospital)
Abstract
This Phase III, randomized, double-blind, placebo-controlled, parallel-group, prospective study based on VAS evaluations clearly showed that orally taken nalfurafine hydrochloride effectively reduced itches that were otherwise refractory to currently available treatments in maintenance haemodialysis patients, with few significant ADRs. This novel drug was officially approved for clinical use in January 2009 by the Ministry of Health, Labour and Welfare of Japan.
Dermatology and Skin DiseasesUrticaria and Related ConditionsAllergic Rhinitis and SensitizationMedicinePlaceboVisual analogue scaleAnesthesiaInternal medicineAgonistClinical endpointAdverse effectPlacebo-controlled studyRandomized controlled trial
MeSH terms
Double-Blind MethodFemaleRenal DialysisHumansMaleMiddle AgedMorphinansPlacebosProspective StudiesPruritusSpiro CompoundsTreatment OutcomeReceptors, Opioid, kappa
Citations
352
FWCI
12.96
field-weighted impact
References
25
Percentile
99%
vs. same field & year
Citations per year
References
Discovery of a Structurally Novel Opioid .KAPPA.-Agonist Derived from 4,5-Epoxymorphinan.
Chemical and Pharmaceutical Bulletin · 1998 · 187 citations
Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS)
Nephrology Dialysis Transplantation · 2006 · 619 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.